<DOC>
	<DOC>NCT00268645</DOC>
	<brief_summary>The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine</brief_summary>
	<brief_title>Insulin Glargine in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patients, Diabetic patients receiving insulin or patients who are insulinnaive and whose glycemic control cannot be sufficiently maintained with single or combined oral antidiabetic agents, Patients with HbA1C&gt;8 Patients able to selfmeasure its blood glucose levels. According to package insert information (Summary of Product Characteristics)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>